Filing Flows › Health Care › Flyte Aviation (VTAK)
Flyte Aviation (VTAK) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 14, 2026 · Flyte Aviation (VTAK) Q2 2026 earnings results →
Q2 2026 Revenue up 381% year over year to $1.0M · 324¢ of every $1 of revenue lost · operating margin -388.1%
Flyte Aviation made $1.0M in Q2 2026 (+381% Y/Y): Service $749K, Product $270K. Operating margin -388.1%, net loss $3.3M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 14, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $1.0M in Q2 2026, up 381% year over year and up 136% from the previous quarter. Service was the largest line at 74% of revenue. Product added $58K year over year (up 27%), 7% of the total change.
Gross margin was 9.6%, down 83.8 points from Q2 2025. Operating costs exceeded revenue by $4.0M, an operating margin of -388.1%. Operating expenses fell 17% while revenue rose 381%. The fastest-growing cost line was SG&A (+36%). The quarter ended with a net loss of $3.3M, wider than the previous quarter's $1.7M loss. Minority interests bore $11K of it: to shareholders the quarter was a loss of $3.3M.
Operating cash flow was −$2.9M. Non-cash charges added back $382K of depreciation and amortization and $266K of share-based compensation. Working capital and other items used $203K. Capital expenditures of $15K exceeded it, leaving free cash flow of −$2.9M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 14, 2026 | $1.0M | +381% | -388.1% | −$3.3M | −$2.9M |
| Q1 2026 | 10-Q | May 18, 2026 | $432K | +202% | -536.6% | −$1.7M | −$2.8M |
| Q4 2025 | 10-K | Mar 31, 2026 | $238K | +60% | n/m | −$5.8M | −$1.5M |
| Q3 2025 | 10-Q | Nov 13, 2025 | $226K | +135% | n/m | −$2.3M | −$2.2M |
| Q2 2025 | 10-Q | Aug 11, 2025 | $212K | +128% | n/m | −$5.5M | −$2.3M |
| Q1 2025 | 10-Q | May 14, 2025 | $143K | +74% | n/m | −$4.0M | −$2.3M |
| Q4 2024 | 10-K | Mar 31, 2025 | $149K | +16% | n/m | −$27.7M | −$2.9M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Flyte Aviation
The registrant (together with our consolidated operating subsidiary, the “Company” or “Catheter”) was incorporated under the name “Ra Medical Systems, Inc.” as a Delaware corporation in July 2018. A predecessor had been incorporated in California in September of 2002, but was reincorporated in 2018 in connection with our initial public offering. The Company was initially formed to develop, commercialize and market an excimer laser-based platform for use in the treatment of vascular and dermatological immune-mediated inflammatory diseases, including the DABRA product line.
In its own words, from its 10-K, filed Mar 31, 2026.
Flyte Aviation against its Surgical & Medical Instruments & Apparatus peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +381% against the peers' median +5%. Operating margin: -388.1% against the peers' median 13.3%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| VTAK Flyte Aviation | Q2 2026 | $1.0M | +381% | -388.1% |
| MDLN Medline | Q3 2026 | $7.9B | +10% | 6.4% |
| MMM 3M | Q3 2026 | $6.6B | +1% | 23.7% |
| SYK Stryker | Q3 2026 | $6.5B | +8% | 15.9% |
| BSX Boston Scientific | Q3 2026 | $5.1B | +1% | 16.1% |
| BDX Becton Dickinson | Q3 FY26 | $5.0B | +5% | 13.3% |
| BAX Baxter International | Q3 2026 | $3.0B | +5% | 7.6% |
| SOLV Solventum | Q3 2026 | $1.9B | -7% | 3.5% |
| RMD ResMed | Q1 FY27 | $1.4B | +6% | 32.0% |
Source: Flyte Aviation 10-Q on SEC EDGAR · CIK 1716621 · Surgical & Medical Instruments & Apparatus
More on VTAK
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results